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Abstract
Background: Contemporary HIV care may reduce frailty in older adults living with HIV (OALWH). Objective of the
study was to estimate prevalence of frailty at the age of 50 and 75 years, and build a model to quantify the burden
of frailty in the year 2030.
Methods: This study included OALWH attending Modena HIV Metabolic Clinic between 2009 and 2015. Patients are
referred from more than 120 HIV clinics well distributed across Italy, therefore being country representative. Our model
forecasts the new entries on yearly basis up to 2030. Changes in frailty over a one-year period using a 37-variable frailty
index (FI) and death rates were modelled using a validated mathematical algorithm with parameters adjusted to best
represent the changes observed at the clinic. In this study, we assessed the number of frailest individuals (defined with
a FI > 0.4) at the age of 50 and at the age 75 by calendar year.
Results: In the period 2015–2030 we model that frailest OALWH at age 50 will decrease from 26 to 7%, and at the age
of 75 years will increase from 43 to 52%. This implies a shift of the frailty prevalence at an older age.
Conclusion: We have presented projections of how the burden of frailty in older adults, living with HIV will change.
We project fewer people aged 50+ with severe frailty, most of whom will be older than now. These results suggest a
compression of age-related frailty.
Background
The World Health Organization (WHO) views popula-
tion aging as one of the most important demographic
changes in society [1]. Globally, the proportion of elderly
people is growing at 2% per year, much faster than the
population as a whole [1]. Worldwide, between 2000
and 2050, the proportion of the people over 60 years is
expected to double.
Aging of the population is becoming a top priority in
health policy [2]. With aging comes an increased preva-
lence of most diseases, which tend to co-occur in older
people [2]. In this context, the demographic modifications
occurring among HIV patients are not an exception but
rather a paradigm of this changing scenario [3]. Globally
35.3 million people are living with HIV, and among them
an estimated 3.6 million are people aged 50 years or older
[4]. Older adults living with HIV (OALWH) represent a
heterogeneous population almost equally distributed
between people aging with HIV and people who acquired
HIV at an older age [5]. The advent of early, effective
combination antiretroviral therapy (ART) and contempor-
ary HIV care has allowed an increasing number of HIV
patients to live into old age. The median age of HIV-
positive patients receiving ART is projected to increase
from 43.9 in 2015 to 56.6 in 2030, as the proportion of
HIV-positive patients aged 50+ years increases from 28 to
73% during the same timeframe. With aging, the clinical
complexity in the HIV-positive population will increase.
For example, the number of people with one non-
communicable disease (NCD) is expected to be 84% by
2030, and the proportion with multi-morbidity (3+
illnesses) to be 28% [6].
Geriatric medicine, more than twenty years ago, has
introduced the term “frailty” to define a condition
caused by the reduction of homeostatic reserves
exposing the individual to higher risk of negative
outcomes [7].
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Frailty is an independent predictor of several adverse
clinical outcomes in older persons, including multi-
morbidity (MM), falls, disability, nursing home place-
ment, and death [8]. In particular, the detection of frailty
has been repeatedly advocated for taking preventive
actions against disability in older persons [9, 10].
Both in the general populations and in HIV/AIDS
setting, frailty has been used to define a specific geriatric
syndrome [11] but also as a state of vulnerability for
adverse outcomes [12]. Frailty is considered an interval
parameter reflecting the “biological age” of the individ-
ual, and might represent much more than a mere condi-
tion to be screened. As argued recently, it may indeed
meet the criteria for making public health decisions [10].
In this framework frailty allows to assess clinical and
biological features, which have been indecently shown to
robustly affect the vulnerability of individuals, notably in
their mortality risk, regardless chronological age, [13].
Several reports have described that the prevalence of
frailty is double in HIV patients when compared to HIV
negative matched controls [14]. In this context, similarly
to what public health is pursuing in compressing chronic
diseases to a shorter period later in life [15, 16], we
hypothesized that contemporary integrated care in HIV
medicine may progressively lead to a “compression of
frailty at an older age” with reduction of frailty in adults
living with HIV and restrain frailty to a later stage of
age. This study estimates the prevalence of frailty in
OALWH at the age of 50 and 75 years, and presents a
model estimating the burden of frailty up to 2030.
Methods
The Modena HIV Metabolic Clinic (MHMC) is a
tertiary level center for diagnosis and treatment of lipo-
dystrophy, NCDs and frailty in HIV people, started in
2003. HIV patients attending MHMC are referred from
more than 120 HIV clinics well distributed across Italy
therefor being country representative. Previous sensitiv-
ity analyses showed that referred patients are similar to
local (Modena province) whole HIV cohort with no case
selection bias [15].
The service prospectively follows patients with free-of-
charge visits with infectious disease physicians, geriatri-
cians, occupational therapists, nutritionists, psychologists,
cardiologist, nephrologists, endocrinologists, and plastic
surgeon consultants. At each visit, patients receive a
multidimensional evaluation, including clinical, anthropo-
metric, physical performance, and neurocognitive assess-
ments. All the data are recorded in a dedicated electronic
health record which integrates health care workers’ assess-
ments with patients related outcomes, including geriatric
syndromes (falls, urinary incontinence, etc.), quality of life
and disability. The MHMC electronic health record
provides a standardized comprehensive tool to describe
changes of frailty over time at an individual level. The
present analyses include 2982 ART-treated HIV-positive
subjects, aged more than 18 years, who were consecutively
evaluated at the Metabolic Clinic of the University of
Modena and Reggio Emilia between 2006 and 2015.
Demographic factors of interest included age and sex.
HIV-specific characteristics included HIV and antiretro-
viral therapy (ART) duration, nadir and current CD4+ T
cell count.
Frailty index (FI)
Frailty was operationalized using a Frailty Index (FI) which
was previously validated and included 37 health variables
routinely collected at each clinical visit (Additional file 1:
Table S1), [17]. Each variable included in the FI was coded
with the value of 1 when a deficit was present and 0 when
absent. The FI for each patient visit was calculated as the
ratio between the number of deficits present and the total
number of deficits assessed. Missing values were removed
from both the numerator and denominator of the FI. Each
FI was computed when a minimum of 80% of valid data for
the health variables was available [18]. Of note, the health
variables that were selected as outcomes or covariates of
interest for this study were excluded from the computation
of the FI.
The FI has been found to predict risk in increments as
low as 0.01, as well as 0.10. For a clinical study, we chose
increments of 0.10. Recognizing that there would be very
few people with low FI counts in a clinical sample, and
that there is poor survival at high FI scores we grouped
participants into the following four categories: fit < 0.2,
pre frail 0.2–0.3, frail 0.31–0.39, and frailest > 0.40 [18].
In this study a novel metric, termed the frailty com-
pression ratio (FCR), was developed to determine the
change in relation between frailty and chronologic age
over time. The FCR was defined as the fraction between
the number of frailest individuals (defined as those with
an FI > 0.4) at the age of 75 divided by the number of
frailest individuals at the age of 50 among OALWH at-
tending the MMHC. An increase in this ratio represents
a shift of the prevalence of frailty towards an older age.
Multimorbidity
Multi-morbidity was defined as ≥3 NCDs occurring in
the same individual among hypertension, diabetes, car-
diovascular disease (CVD), dyslipidaemia, chronic ob-
structive pulmonary disease (COPD), chronic kidney
disease (CKD), fractures, liver cirrhosis and cancer [19].
Ethics
Approval for the Modena HIV Metabolic Clinic Cohort
was obtained from the Research Ethics Board of the
University of Modena and Reggio Emilia, and all
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participants provided written consent (Study reference
254/12, protocol 883/CE, date 7th March 2013).
Statistical analysis
Using clinic data collected between 2006 and 2015, we
constructed an individual-based model of the aging
population attending the MHMC. The model follows pa-
tients enrolled in the MHMC up to December 2015,
until death or end of the model simulation in 2030, esti-
mating outcomes such as FI and MM at one-year time
intervals. Similarly, the model generates new entries into
the MHMC for each year from 2016 to 2030 and follows
them (until death or end of 2030) on a yearly basis.
Predictions of the model for the first two years (2016
and 2017) were validated using data collected in the cor-
responding years to ensure projections were pointing in
the right direction.
The number of new entries from 2016 to 2030 was
simulated projecting trends observed from 2006 and
2015 in the MHMC. Gender was assigned probabilistic-
ally to new patients using the observed male to female
ratio. Age of each new patient was randomly generated
from a gamma distribution with gender- and year-
specific parameters (mean and standard deviation) pro-
jected from trends observed between 2006 and 2015.
Similarly, nadir CD4+ T cell count and time since HIV
infection were randomly generated from normal distri-
butions with age-, gender- and year-specific parameters.
The prevalence of each NCD was determined in the
whole population and in age-defined groups (18–39, 40–
44, 45–49, 50–54, 55–59, 60–64 and ≥ 65) and Chi-
squared test for trend was used to compare the
prevalence of NCDs across age groups and test for sig-
nificant trends. Continuous outcomes were summarised
using the median and interquartile range (IQR).
Occurrence of MM at model entry was probabilistic-
ally assigned to new patients based on rates modelled
using age, gender, time since HIV infection and nadir
CD4+ T cell count. The contribution of each of these
factors to estimate the rate was obtained from a multi-
variable mixed-effect logistic regression model. For each
simulated year, new patients and patients already
enrolled in the MHMC before 2016 were followed as
they age and eventually die, simulating changes in FI
and MM.
The number of deficits (used to calculate the FI) at the
time of entry into the MHMC for each new patient was
randomly generated from a Poisson distribution with
mean depending on age, gender, time since HIV infec-
tion, and nadir CD4+ T cell count. Weights for each of
these factors (to estimate the mean of the Poisson distri-
bution) were obtained from a multivariable mixed-effect
Poisson regression model predicting the FI in the popu-
lation of the MHMC from 2006 to 2015. Changes in FI
over a year were modelled using a normal distribution
with parameters depending on age, gender, time since
HIV infection, nadir CD4+ T cell count and FI in the
previous year. The generated number was then added to
the FI of the previous year.
Death rates were obtained from a validated mathemat-
ical model which estimates the probability of dying in a
given period of time based on the FI at the beginning of
the period of time. This model was developed in a large
Canadian aging population [20] and parameters were
adjusted to best represent the death rates observed in
the MHMC.
The probability of having a FI score > 0.40 (frailest
individuals) and that of MM at any given year was esti-
mated using polynomial logistic regression models with
age as independent variable and with the degree of the
polynomial that minimized the variance of the model or
when there was no significant decrease in its value as
the degree of polynomial is increased. The probability of
being at the frailest category (i.e. FI > 0.40) for individ-
uals of 50 and 75 years was then calculated at each year
between 2016 and 2013 and used to estimate the frailty
compression ratio (FCR) for coming years.
Linear regression models were used to test significant
time trends (from 2006 to 2015) in the distribution of
age, time since HIV infection and start of ART, nadir
CD4+ T cell count, proportion of late presenters and
patients referred to the clinic after 20 years or more
since HIV infection. Models were conducted separately
in women and men and were aimed at identifying chan-
ging factors in MHMC in the period 2009–2015 which
may have justified model’s predictions.
All the analyses (including model simulations) were
performed using the statistical software R version 3.3.1.
Results
The 2982 HIV-positive patients enrolled in the MHMC
and alive at the end of December 2015 were mainly men
who were taking anti-retroviral therapy (Table 1).
Socio-demographic, anthropometric, lifestyle and HIV-
specific characteristics are summarized in Table 1.
Median time since HIV diagnosis was 19.7 (IQR 12.8,
24.4) years and the median nadir CD4+ T cell count was
200 (IQR 86, 300) cells/μL.
Among the NCDs, most participants (82.1%) had dys-
lipidemia, followed by hypertension (36.8%) osteoporosis
(20.5%) and cirrhosis of the liver (12.3%). Fewer than 5%
had type 2 diabetes, CVDs, cancer, COPD and CKD.
The prevalence of all NCDs increased significantly with
age (Additional file 1: Figure S1).
The model predicts that the median age of patients
evaluated at MHMC will increase from 49 (IQR 45, 54)
years in 2015 to 63 (IQR 58, 77) years in 2030. The pro-
portion of patients older than 50 years is predicted to
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increase from 48.2% in 2015 to 95.6% in 2030, whereas
the proportion of patients aged 65 years or older will in-
crease from 4.3 to 38.1%. In particular, the proportion of
people aged 75 years or older will increase from 0.6 to
4.3% (Fig. 1, panel A). As a result of the aging HIV-
positive population, the number of patients with MM is
expected to increase from 52.3% in 2015 to 62.1% in
2030 (Fig. 1, panel B). Our model suggests that the pro-
portion of frail patients (FI > 0.3) will increase from
25.8% in 2015 to 28.0% in 2030 and frailest patients (FI >
0.4) will increase from 23.8 to 48.2% (Fig. 1, panel C).
Figure 2 estimate that the probability of MM at age of
50 decreased from 37.8 to 11.7% while at the age of 75
the probability of MM went from 99.8 to 96.8%. In par-
allel, there was a significant reduction of the probability
of frailty at the age of 50 from 26.0 to 7.0%, and an in-
crease at the age of 75 from 42.7 to 51.8% in the same
time frame.
Figure 3 shows projections of the proportion of frailest
individuals at the age of 50 (blue bar) and at the age of
75 (orange bar). The ratio of these two proportions at
each year is the FCR and it is represented by the red
dotted line. FCR will increase from 1.6 to 7.4 from 2015
to 2030.
We explored the factors that may have contributed to
the FCR. Proportion of male patients (rho = 0.71, p <
0.01), age (rho = 0.56, p = 0.056), nadir CD4+ T cell
count (rho = 0.86, p < 0.001) and proportion of patients
with HIV duration more than 20 years (rho = 0.84, p <
0.001) correlated with frailty compression in univariable
analysis. Association was not statically significant for
time exposure of antiretroviral treatment (ART), time
lag between HIV diagnosis and ART initiation and pro-
portion of HIV late presentation (CD4 < 350 cells/μL).
Proportion of male patients (p = 0.02), age (p < 0.001),
nadir CD4+ T cell count (p < 0.001) and proportion of
patients with HIV duration more than 20 years (p =
0.001) remained significantly associated even in multi-
variable analysis.
Discussion
This is the first modelling study quantifying the bur-
den of MM and frailty in relation to demographic
projections estimated in an HIV Italian cohort. This
model shows an increase in the burden of MM and
Table 1 Socio-demographic, anthropometric lifestyle and HIV-
specific characteristics




Age (years) 49 (45, 54)
Weight (kg) 68.0 (59.6, 76.6)
Height (cm) 170 (163, 176)
BMI (kg/m2) 23.5 (21.4, 26.0)
Waist (cm) 87 (81, 94)
Hip (cm) 92 (88, 97)
Waist-to-Hip ratio 0.95 (0.90, 1.00)
Smoking
No smoking 1756 (58.9%)
1–10 cigarettes per day 516 (17.3%)
> 10 cigarettes per day 672 (22.5%)
Missing 38 (1.3%)
Alcohol consumption
No consumption 1766 (59.2%)
Mild consumption 1149 (38.5%)
Intense consumption 31 (1.1%)
Missing 36 (1.2%)
Physical activity
No physical activity 1484 (49.8%)
Mild physical activity 1206 (40.4%)
Intense physical activity 265 (8.9%)
Missing 27 (0.9%)
Likely route of transmission, n (%)
Homosexual sex 881 (29.5%)
Heterosexual sex 1014 (34.0%)
IVDU/Blood product 778 (26.1%)
Other/unknown 309 (10.4%)





Years since HIV diagnosis 19.7 (12.8, 24.4)
Currently on ART 2810 (92.5%)
Time since start of ART (years) 5.2 (2.6, 7.8)
Number of drugs 3 (3, 4)
Currently on NRTIs 2319 (82.5%)
Currently on PIs 1550 (55.2%)
Currently on NNRTIs 1103 (39.3%)
Currently on other drugs 569 (20.6%)
Table 1 Socio-demographic, anthropometric lifestyle and HIV-
specific characteristics (Continued)
Variable, n (%) or median (IQR) HIV-positive (N = 2982)
CD4+ T cell count (cells/μL) 648 (474, 841)
CD8+ T cell count (cells/μL) 815 (601, 1113)
CD4+: CD8+ ratio 0.80 (0.57, 1.10)
CD4+ T cell count (cells/μL) 200 (86, 300)
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frailty in the year 2030, indicative of an accentuated
health profile expected by the aging epidemic affect-
ing OALWH, as previously shown by the Athena co-
hort projections [4].
Frailty as primary end point of this study reflects a
geriatric approach which considers frailty as the best in-
dicator to describe the complexity and heterogeneity of
aging.
Fig. 1 Prediction of median age, multi-morbidity and frailty in PLWH. Panel a. The median age predictions of patients from 2015 to 2030. Panel b.
The proportion of patients with multi-morbidity from 2015 to 2030. Panel c. The distribution of frailty index values from 2015 to 2030
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We chose to operationalize frailty with FI rather than
with frailty phenotype because given the continuous
metric of former, make this tool more suitable to
describe trajectories over time [21].
Being based on arithmetic and not clinical assump-
tions, frailty index is more suitable than others for an
immediate translation of the frailty concept from geriat-
rics to the HIV medicine world given its quantitative
nature [22].
The burden of frailty in OALWH by the year 2030
should not be interpreted as an apocalyptic scenario
since this projection shows that these conditions will be
compounded to older age. In fact, it is not alarming that
50% of HIV patients will be most frail at the age of 75, it
simply shows that the aging HIV-positive population
may gradually get closer to the clinical manifestations of
the general geriatric population.
It may be questioned the reason why at present, a rela-
tively low number of people aged > 75 are frail. First of
all, people belonging to this age group are few. More-
over, it can also be assumed a survival bias and therefore
people in this age group may really represents “cham-
pions” of their generation, being able to live longer with
HIV infection or getting HIV at an older age [17].
The crux of the study is the development of the con-
cept of frailty compression at an older age. To our
knowledge this measure, that we have translated into an
algorithm which consider the ratio of the proportion of
frailest individuals at the age of 75 and at the age of 50
years at any given year, is original in geriatric medicine
Fig. 2 The probability of multi-morbidity and frailty in 2015, 2020 and 2030
Fig. 3 Projections of the proportion of frailest individuals at the age of 50 (blue bar) and at the age of 75 (orange bar)
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also. Given the tight connection between MM and
frailty, we believe that measuring the deficit accumula-
tion will allow us to monitor trajectories of a healthy
aging, regardless of the co-occurrence of age-associated
NCDs.
The striking finding from our cohort is that the preva-
lence of frailest individuals at the age of 50 years
decreased in the past decade. What happened in
OALWH attending MHMC is a unique and favorable
phenomenon of frailty compression to older age. This
was associated with a profound changing in immuno-
logical characteristics of the patients depicted by higher
nadir CD4 and a higher proportion of people living with
HIV longer than 20 years. The former may document a
reduction in the proportion of OALWH with a perman-
ent immunological scar associated with advanced HIV
disease, the latter, healthier patients living with HIV with
better immunological profile.
We are not aware of other disease model in which
frailty compression was so apparent: at MHMC the pro-
portion of frailest individual at 50 years of age halved in
the past 10 years. Therefore, we hypothesize that the
immunological characteristics which stand behind this
favorable immunological improvement observed in
OALWH may be found also in HIV negative individuals
experiencing healthy aging.
Recognition of frailty change in term of prevalence
and age of onset in HIV patients will contribute to re-
shape our healthcare systems. HIV geriatric medicine
implies a structural and a cultural change in patient as-
sessment focused on older person’s functional ability,
physical health, cognition, quality of life and socio-
environmental circumstances rather than assessing pa-
tient’s comorbidities [22].
Interdisciplinary team members (e.g. nurses, social
workers, pharmacists, psychologists and occupational
therapists) can administer screening tools to both save
time and help the team to focus on specific limitations
that need more detailed evaluation. The goal of preven-
tion is there for not just avoiding mortality as an obvious
negative end point, but rather reaching a disability free
survival in a healthy aging process [3].
Some weakness of the study must be acknowledged.
The projection model is obviously itself a model there-
fore prone to errors. Second, it is based on the retro-
spective analyses of patients enrolled in a clinical cohort
which may not generalize to the whole HIV-positive
population worldwide.
A point of strength of the study is the original use of
FI as an epidemiological tool to make a projection using
a global health perspective. The unprecedented rapid
change of clinical care observed in the past 30 years,
once again pilot new epidemiological scenarios for
public health in which the comprehensive geriatric
assessment evaluates frailty at screening and contempor-
ary targets this condition in an adapted individualized
approach [23]. This approach particularly fits PLWH
where many individuals are frail regardless their rela-
tively young age [24] and allows a holistic and personal-
ized care.
Conclusions
In conclusion, we have presented projections of how the
burden of frailty in older adults, living with HIV will
change. We project fewer people aged 50+ with severe
frailty, most of whom will be older than now. These re-
sults suggest a compression of age-related frailty.
Additional file
Additional file 1: Figure S1. Prevalence of comorbidities by age group.
Table S1. Health variables included in the frailty indices and description
of deficit scoring. (PDF 414 kb)
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